FDA clears IS2’s NuCammas
Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by
Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by founder Iain Stark, formerly of Park Medical. They were introduced at this years Society of Nuclear Medicine meeting (SCAN 8/5/98).
NuCamma C+ has a circular field of view, while NuCamma Rx is a rectangular system. The electronics of both units are incorporated into their detectors, and the systems will carry list prices between $150,000 and $190,000. The Nepean, Ontario-based company has almost completed the manufacturing of its first batch of 10 cameras.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
